Williams Thomas R, Benjamin Tavya G R, Schwartz Michael J, Rastinehad Ardeshir R
The Smith Institute for Urology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, New York, NY, USA.
Ann Transl Med. 2023 Jan 15;11(1):24. doi: 10.21037/atm-22-2337. Epub 2022 Nov 30.
Prostate cancer (PCa) has seen improved detection methods with a subsequent rise in disease prevalence, making novel prostate cancer treatment options an exciting yet controversial topic. Current treatment modalities encompass traditional approaches, namely surgery (radical prostatectomy) and radiation therapy. While heralded as a standard of care, these modalities may come with significant risk profiles, primarily sexual (erectile dysfunction) and urinary incontinence. Advances in technology and imaging, specifically multi-parametric MRI, have afforded great leaps in targeted focal therapy as a primary treatment option for localized PCa. This review identifies and highlights published data for novel and emerging PCa focal therapy (FT) modalities.
Our study identified and reviewed the current literature for relevant investigations related to primary FT modalities as they apply to the treatment of prostate cancer. After an internal review, relevant studies (published in English, between 2000-April 2022) were included for analysis and summarization.
We provide a concise review of several novel focal therapy modalities that offer realistic potential for primary treatment of localized prostate cancer. Our narrative includes studies that primarily include their respective results, specifically focusing on those that reported both oncologic and quality-of-life outcomes after focal therapy. While still in its cumulative infancy, we discuss the current limitations, future directions, and advancements that hopefully push focal therapy into the limelight.
While many of the mentioned focal therapies for PCa have shown promising pathologic and quality of life outcomes, further clinical evidence is required to change overall management guidelines and recommendations. The advantages of FT in avoiding sexual and urinary side-effects of radical surgery or radiation are apparent; however, it is necessary to recognize the need for further long-term evidence that is durable over time and comparable to current gold-standard treatment options.
前列腺癌(PCa)的检测方法有所改进,疾病患病率随之上升,这使得新型前列腺癌治疗方案成为一个令人兴奋但颇具争议的话题。当前的治疗方式包括传统方法,即手术(根治性前列腺切除术)和放射治疗。尽管这些方式被誉为标准治疗方法,但可能伴随着重大风险,主要是性功能方面(勃起功能障碍)和尿失禁。技术和成像技术的进步,特别是多参数MRI,使靶向聚焦治疗作为局限性PCa的主要治疗选择取得了巨大飞跃。本综述确定并突出了已发表的关于新型和新兴PCa聚焦治疗(FT)方式的数据。
我们的研究确定并回顾了当前文献中与适用于前列腺癌治疗的主要FT方式相关的研究。经过内部评审,纳入了相关研究(2000年至2022年4月期间以英文发表)进行分析和总结。
我们简要回顾了几种新型聚焦治疗方式,这些方式为局限性前列腺癌的主要治疗提供了切实可行的潜力。我们的叙述包括主要涉及各自结果的研究,特别关注那些报告了聚焦治疗后肿瘤学和生活质量结果的研究。虽然仍处于发展初期,但我们讨论了当前的局限性、未来方向以及有望使聚焦治疗成为焦点的进展。
虽然许多上述PCa聚焦治疗已显示出有前景的病理和生活质量结果,但仍需要进一步的临床证据来改变整体管理指南和建议。FT在避免根治性手术或放疗的性和泌尿系统副作用方面的优势显而易见;然而,有必要认识到需要进一步的长期证据,这种证据要能长期持续且可与当前的金标准治疗方案相媲美。